about
Towards the targeted management of Chediak-Higashi syndromeSLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects[Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity.An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets.Wiskott-Aldrich syndrome in a child presenting with macrothrombocytopenia.Evaluation of Novel Platelet Polymorphisms in Stroke. Dichotomic Effect of rs5443 in GNB3.Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: results from a collaborative study.Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children.Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system.Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction.New perspectives in antiplatelet therapy.Hermansky-Pudlak syndrome. Overview of clinical and molecular features and case report of a new HPS-1 variant.Generation of a human induced pluripotent stem cell (iPSC) line from a Bernard-Soulier syndrome patient with the mutation p.Asn45Ser in the GPIX gene.ISTH Advanced Training Course on platelet bleeding disorders: How should they be investigated?St. Anne's College, Oxford, 6-9th September 2016.Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets.Proteomic analysis of platelet N-glycoproteins in PMM2-CDG patients.Chediak-Higashi syndrome: description of two novel homozygous missense mutations causing divergent clinical phenotype.Identification of two novel mutations in RASGRP2 affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis.A dietary resveratrol-rich grape extract prevents the developing of atherosclerotic lesions in the aorta of pigs fed an atherogenic diet.Rare homozygous status of P43 β1-tubulin polymorphism causes alterations in platelet ultrastructure.Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold.An exit strategy for new platelets.Evaluation of two-step haemoglobin screening with HemoCue for blood donor qualification in mobile collection sites.Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation.Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: identification of the second HPS7 mutation in a patient presenting late in lifeHsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding riskComparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantationHigh on-treatment platelet reactivity in patients with ischemic cerebrovascular diseaseQuality assessment of buffy-coat-derived leucodepleted platelet concentrates in PAS-plasma, prepared by the OrbiSac or TACSI automated systemInfluence of CYP2C19 Polymorphisms in Platelet Reactivity and Prognosis in an Unselected Population of Non ST Elevation Acute Coronary SyndromeIn vitro analysis of platelet concentrates stored in the presence of modulators of 3′,5′ adenosine monophosphate, and organic anionsImpaired hemostatic activity of healthy transfused platelets in inherited and acquired platelet disorders: Mechanisms and implicationsRASGRP2 gene variations associated with platelet dysfunction and bleedingIdentification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencingABCG5 and ABCG8 gene variations associated with sitosterolemia and platelet dysfunction
P50
Q26829320-B9EE6F58-4670-4D04-93BF-5AC2730D3BDCQ29147411-7ED1EFDF-5985-46CB-9849-9E62989AB2B7Q33396453-1D952CB6-DDB6-4D5C-9D41-4759E2D5E2BCQ33402393-38CA18A3-FDEB-4DDE-A67D-77A77D46A958Q33422982-1B9D2AC7-F230-4D05-8884-812C6DC1E0A9Q33437105-4FA5E04D-0F3E-4155-93A1-539CAB47934FQ34996505-DB172A4B-D9F9-462C-9644-5B4E25F0131CQ34998085-C97829D3-4B36-42BA-94B8-6B504691268AQ35193732-D6286AF9-FE4C-41B8-B9E3-2C45EF12F3A2Q36393452-0A823804-ED03-44D4-B259-DED61C29B410Q37228334-FC4A3B2E-4185-46CF-86D9-63EB51145B32Q37984115-5FA854CD-8627-4677-A445-B8C56BA077DEQ38239378-2821C64D-A54B-4137-BA41-480388960B43Q40433186-E38455AF-5F16-40BA-84B1-23C966F5D65CQ40453216-93855893-049A-4434-B866-E42FE5B1F021Q42951363-6374321B-2318-457B-A056-BDC19163BBE2Q45861243-498D87F1-11D8-4CCC-AD9E-71F1A7FED894Q46717978-25887DCA-1B17-47C6-A59D-80B5DF311B58Q48005509-7F4B154B-19D4-4766-B38F-F43BFB5BD54CQ49171218-CB4CC903-B4E4-495A-AACE-8CE608D89C5AQ50113632-920E82F8-385D-4235-A9B8-A92C1C2BA7F6Q51306353-BA4AA896-8C49-412B-8452-655AEBEA53A1Q52665779-AEAEF871-172C-4B50-91D2-BD00F698AAABQ53146385-17062501-1DE6-4445-9D8E-8BAC9089B198Q54261864-D9F2CF82-1EA7-4588-99FA-17B34715942AQ57078434-D50DE4C6-7BEC-4AFB-904F-70D0DA53B216Q61780692-FF7137B0-761F-4D5D-8489-81C4B8CA7C59Q62090477-3DADA878-E76F-4443-8EAD-DA36D16E7AC4Q62090491-8494D4A3-894D-4073-B93C-6C137206EDA8Q62090492-7FC52CC0-01F7-4141-B183-FD36147B7CE1Q62090494-65742CB0-42E6-4611-8351-6FFA99B8879DQ62090539-A587C82B-A5DD-4447-818A-EF29C39D9D06Q91890070-2022D221-B3FB-4A44-904C-D57226892A25Q92228955-71D5F6FC-7228-4132-91BD-32809FD68D61Q93122477-F8A6CE21-CAD5-4E34-AF1E-2755C695D941Q96430096-949F1740-0853-4CFE-9514-544A0297F661
P50
description
researcher ORCID ID = 0000-0003-4225-6840
@en
wetenschapper
@nl
name
J Rivera
@ast
J Rivera
@en
J Rivera
@nl
type
label
J Rivera
@ast
J Rivera
@en
J Rivera
@nl
prefLabel
J Rivera
@ast
J Rivera
@en
J Rivera
@nl
P31
P496
0000-0003-4225-6840